RUA Life Sciences plc provided earnings guidance for the 12 months to 31 March 2022. For the period, the company expected to have generated consolidated unaudited revenues of £1,625,000 (2021: £1,528,000), an increase of 6% over the same period in the previous year. Overall, loss before tax for the period is expected to have increased to £2,360,000 (2021: £1,594,000) which resulted from a combination of increased R&D activities and further investment in the infrastructure to support future growth.